Use of risk determinants for different breast cancer prevention strategies

被引:6
作者
Dowsett, M [1 ]
机构
[1] Royal Marsden Hosp, Acad Dept Biochem, London SW3 6JJ, England
关键词
breast cancer; oestrogens; prevention; risk profiles; oestrogen deprivation; GnRH agonists;
D O I
10.1016/S0959-8049(00)00101-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Almost all of the factors which are known to be associated with a high risk of breast cancer, other than high genetic risk, are associated with increased exposure to oestrogens. Thus, therapeutic manoeuvres targeted at oestrogen deprivation which have shown value in established breast cancers are attractive candidates for breast cancer prevention strategies. It is possible that such agents may reduce the incidence of ER-negative as well as ER-positive rumours. The potential use of these different drugs is restricted by menopausal status, e.g. aromatase inhibitors only after the menopause, and Gonadotropin-releasing hormone (GnRH) agonists prior to the menopause. There is a complex interplay between the anticipated benefit which may be derived from a respective agent and the side-effects associated with it. This article seeks to integrate the information From several sources and concludes that the prophylactic strategies should differ according to different risk profiles. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1283 / 1287
页数:5
相关论文
共 27 条
  • [1] Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
  • [2] Bramley M. D., 1997, Breast Cancer Research and Treatment, V46, P26
  • [3] Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: Comparison between tamoxifen-treated and nontreated breast cancer patients
    Cohen, I
    Figer, A
    Tepper, R
    Shapira, J
    Altaras, MM
    Yigael, D
    Beyth, Y
    [J]. GYNECOLOGIC ONCOLOGY, 1999, 72 (02) : 202 - 207
  • [4] DEWAARD F, 1981, BANBURY REPORT, V8, P21
  • [5] Dowsett M, 1997, ANN ONCOL, V8, P631
  • [6] Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial
    Ettinger, B
    Black, DM
    Mitlak, BH
    Knickerbocker, RK
    Nickelsen, T
    Genant, HK
    Christiansen, C
    Delmas, PD
    Zanchetta, JR
    Stakkestad, J
    Glüer, CC
    Krueger, K
    Cohen, FJ
    Eckert, S
    Ensrud, KE
    Avioli, LV
    Lips, P
    Cummings, SR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07): : 637 - 645
  • [7] Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
    Fisher, B
    Costantino, JP
    Wickerham, DL
    Redmond, CK
    Kavanah, M
    Cronin, WM
    Vogel, V
    Robidoux, A
    Dimitrov, N
    Atkins, J
    Daly, M
    Wieand, S
    Tan-Chiu, E
    Ford, L
    Wolmark, N
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) : 1371 - 1388
  • [8] PROJECTING INDIVIDUALIZED PROBABILITIES OF DEVELOPING BREAST-CANCER FOR WHITE FEMALES WHO ARE BEING EXAMINED ANNUALLY
    GAIL, MH
    BRINTON, LA
    BYAR, DP
    CORLE, DK
    GREEN, SB
    SCHAIRER, C
    MULVIHILL, JJ
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (24) : 1879 - 1886
  • [9] GONADOTROPIN-RELEASING-HORMONE ANALOG (GOSERELIN) PLUS HORMONE REPLACEMENT THERAPY FOR THE TREATMENT OF ENDOMETRIOSIS - A RANDOMIZED CONTROLLED TRIAL
    HOWELL, R
    EDMONDS, DK
    DOWSETT, M
    CROOK, D
    LEES, B
    STEVENSON, JC
    [J]. FERTILITY AND STERILITY, 1995, 64 (03) : 474 - 481
  • [10] Kelsey J L, 1979, Epidemiol Rev, V1, P74